J Uriach Y Compania SA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:J Uriach Y Compania SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013216
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
J Uriach Y Compania SA (Uriach) is a pharmaceutical company that offers food supplements, cosmetics and OTC products. It also researches, develops and manufactures active ingredients for the pharmaceutical market. Uriach provides antiflatulents, antifungals, mineral supplements and antiplatelet drugs among others. The company offers its products in the form of tablets, powders, capsules, pills, granules, creams and ointments. It also provides contract manufacturing services. Uriach spans its expertise in the development and marketing of generic files for international licensing. It offers products for sleep and relaxation, skin and beauty, energy and sport, irritation and wounds and others. Uriach is headquartered at Barcelona, Spain.

J Uriach Y Compania SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
J Uriach Y Compania SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Palau Pharma Enters Into Agreement With Sensorion To Develop UR-63325 10
Licensing Agreements 12
Uriach Enters into Licensing Agreement with Teikoku Seiyaku for Rupatadine 12
Ahn-Gook Pharm Enters Into Licensing Agreement With Grupo Uriach For Rhinitis Drug 13
Asset Transactions 14
Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 14
Palau Pharma Sells UR-65318 To US Pharma Company 15
Draconis Pharma Acquires Drug Discovery Unit Of Palau Pharma 16
Acquisition 17
Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 17
J Uriach Y Compania SA – Key Competitors 18
J Uriach Y Compania SA – Key Employees 19
J Uriach Y Compania SA – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
May 11, 2016: Uriach grows by 10% in 2015, reinforcing its status as a reference for financial performance in the pharmaceutical sector 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Key Facts 2
J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
J Uriach Y Compania SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
J Uriach Y Compania SA, Deals By Therapy Area, 2011 to YTD 2017 8
J Uriach Y Compania SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Palau Pharma Enters Into Agreement With Sensorion To Develop UR-63325 10
Uriach Enters into Licensing Agreement with Teikoku Seiyaku for Rupatadine 12
Ahn-Gook Pharm Enters Into Licensing Agreement With Grupo Uriach For Rhinitis Drug 13
Actavis Acquires Worldwide Rights To Albaconazole From Palau Pharma 14
Palau Pharma Sells UR-65318 To US Pharma Company 15
Draconis Pharma Acquires Drug Discovery Unit Of Palau Pharma 16
Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 17
J Uriach Y Compania SA, Key Competitors 18
J Uriach Y Compania SA, Key Employees 19
J Uriach Y Compania SA, Other Locations 20
J Uriach Y Compania SA, Subsidiaries 20

★海外企業調査レポート[J Uriach Y Compania SA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Thor Industries, Inc.:企業の戦略・SWOT・財務分析
    Thor Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Thor Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Illumina, Inc.:企業のM&A・事業提携・投資動向
    Illumina, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Illumina, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Central Reinsurance Corporation:企業の戦略・SWOT・財務情報
    Central Reinsurance Corporation - Strategy, SWOT and Corporate Finance Report Summary Central Reinsurance Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • M1 Ltd (B2F):企業の財務・戦略的SWOT分析
    M1 Ltd (B2F) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Bank Of Panhsin:企業の戦略・SWOT・財務分析
    Bank Of Panhsin - Strategy, SWOT and Corporate Finance Report Summary Bank Of Panhsin - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Hopewell Holdings Ltd (54):企業の財務・戦略的SWOT分析
    Hopewell Holdings Ltd (54) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Illovo Sugar Africa Pty Ltd:企業の戦略的SWOT分析
    Illovo Sugar Africa Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Trex Company Inc (TREX):企業の財務・戦略的SWOT分析
    Trex Company Inc (TREX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Indigo Books & Music, Inc.:戦略・SWOT・企業財務分析
    Indigo Books & Music, Inc. - Strategy, SWOT and Corporate Finance Report Summary Indigo Books & Music, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Bioneer Corp (064550):企業の財務・戦略的SWOT分析
    Bioneer Corp (064550) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Gritstone Oncology Inc-製薬・医療分野:企業M&A・提携分析
    Summary Gritstone Oncology Inc (Gritstone) is a cancer immunotherapy company which focuses on the development of personalized cancer therapeutics. The company primarily concentrates on identifying and deploying the therapeutic neo-antigens from individual patients’ tumors for the development of nove …
  • Mission Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Mission Therapeutics Ltd (Mission) is a provider of deubiquitylating enzyme drug discovery and development programs. The company develops USP30, USP10 and UHCL1 for patients with mitochondria diseases, neurodegeneration, inflammation and others. the company uses its proprietaryDUB platform t …
  • Trent Ltd (TRENT):企業の財務・戦略的SWOT分析
    Trent Ltd (TRENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Petroleos Mexicanos-エネルギー分野:企業M&A・提携分析
    Summary Petroleos Mexicanos (PEMEX) is a state owned vertically integrated oil and gas company. The company explores for, develops and produces crude oil and natural gas. It also refines and markets petroleum products. PEMEX gathers and processes natural gas products. It manufactures and markets a w …
  • Avgol Industries 1953 Ltd. (AVGL):企業の財務・戦略的SWOT分析
    Avgol Industries 1953 Ltd. (AVGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Valecha Engineering Ltd:戦略・SWOT・企業財務分析
    Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Valecha Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • American International Group Inc:戦略・SWOT・企業財務分析
    American International Group Inc - Strategy, SWOT and Corporate Finance Report Summary American International Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Langley Holdings plc:企業の戦略・SWOT・財務分析
    Langley Holdings plc - Strategy, SWOT and Corporate Finance Report Summary Langley Holdings plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • TriMedx LLC:企業の戦略的SWOT分析
    TriMedx LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Solaria Energia y Medio Ambiente SA (SLR):企業の財務・戦略的SWOT分析
    Solaria Energia y Medio Ambiente SA (SLR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆